Rheumatologists Eye AbbVie’s Rinvoq, Roche/Genentech’s Gazyva, and Bristol Myers Squibb’s Sotyktu as Front-Runners to Address Persistent Gaps in Systemic Lupus Erythematosus Care, Spherix Global Insights Reports
Rheumatologists expect new mechanisms of action to reshape the SLE landscape as demand grows for safer, more effective options—particularly therapies with steroid-sparing potential and easier administration EXTON, PA, July 23, 2025 — Biologic use in systemic lupus erythematosus (SLE) is steadily rising, with U.S. rheumatologists now treating close to 40% of their moderate-to-severe patients with […]
Survey data shows trends for AMD and DME treatments and future prospects
The survey shows the evolving landscape of nAMD and DME treatments, highlighting physician preferences, payer influences, and the promise of gene therapy advancements. Spherix Global Insights released data that examine the competitive and complex treatment landscape for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). The Q2 wave of the syndicated RealTime Dynamix […]
Access Barriers Hamper Early Line Adoption of UCB’s Bimzelx at Six Months Post-Launch in Psoriatic Arthritis and Axial Spondyloarthritis, According to Spherix Global Insights
Despite early access friction, Bimzelx’s clinical promise and prescriber satisfaction suggest long-term opportunity in PsA and axSpA. Exton, PA., June 2, 2025 – Just over six months into its dual launch across Psoriatic Arthritis (PsA) and Axial Spondyloarthritis (axSpA), UCB’s Bimzelx (bimekizumab) is demonstrating meaningful promise, though prescriber momentum remains tempered by access hurdles and […]
New Biologics Reshape the gMG Landscape, but Growth Opportunities Persist for Established and Pipeline Therapies, According to Spherix Global
High rates of biologic naivety, limited switching, and ongoing unmet needs across the gMG landscape create opportunity for brand differentiation. EXTON, Pa, May 15, 2025 — The treatment landscape for generalized myasthenia gravis (gMG) has entered a new era of therapeutic innovation. Since 2022, seven novel targeted biologics have launched, with a robust pipeline poised […]
Sanofi Garners Highest Physician Interest in Asthma Pipeline, Despite GSK’s Later-Stage Asset, According to Spherix Global Insights
Following a period of stability in the US biologic asthma market, new data reveals hidden opportunities for differentiation and growing prescriber interest in emerging pipeline therapies Exton, PA, May 13, 2025 – Although no new biologics for asthma have been approved since the 2021 launch of Tezspire (Amgen/AstraZeneca), recent insights from Spherix Global Insights point […]
Emerging Treatments Drive Notable Changes in IgA Nephropathy Care Across Key Global Markets, According to Spherix Global Insights
Products such as Tarpeyo (Calliditas), Filspari (Travere) and now Novartis’ Fabhalta and Venrafia provide physicians more options than ever before. Exton, PA, May 8, 2025 – With multiple targeted therapies now available and SGLT2 inhibitors broadly embraced, nephrologists across the globe are redefining how they manage IgA Nephropathy (IgAN) patients. Data from Spherix Global Insights’ […]
Gene Therapy Momentum Builds Among Hematologists in Sickle Cell Disease Management Despite Ongoing Access Barriers, According to Spherix Global Insights
US hematologists express growing confidence in curative gene therapies such as Casgevy and Lyfgenia, while also showing heightened enthusiasm for next-generation disease-modifying agents. Exton, PA, May 01, 2025 – Patients with sickle cell disease (SCD) continue to face severe complications, despite advances in treatment that have helped mitigate some risks. Increased rates of blood clots, […]
Specialists Eye Gazyva as a New Option for Lupus Nephritis, but ACR Guidelines Favor Benlysta and Lupkynis for Upfront Use, According to Spherix Global Insights
The ACR’s updated lupus nephritis treatment guidelines emphasize triple therapy regimens anchored by Benlysta or a calcineurin inhibitor, while Gazyva’s potential role in the evolving landscape remains to be established as the field continues to advance. Exton, PA., April 30, 2025 – The American College of Rheumatology’s (ACR) newly updated treatment guidelines for lupus nephritis […]
Excitement Builds for Tremfya Among US Gastroenterologists as the FDA Approves its Expansion into Crohn’s Disease, Suggesting the Brand May Impact Competitor Skyrizi’s Growth
Gastroenterologists are enthusiastic about Tremfya’s subcutaneous induction option in Crohn’s disease, a key potential brand differentiator, according to Spherix Global Insights. EXTON, PA., March 28, 2025 – The treatment landscape for Crohn’s disease continues to evolve with the recent FDA approval of Johnson and Johnson Innovative Medicine’s Tremfya (guselkumab). This significant milestone makes Tremfya the […]
US Rheumatologists Report Heightened Interest in Sotyktu for the Treatment of Psoriatic Arthritis Post Positive Trial Results, According to Spherix Global Insights
While interest in BMS’s pipeline asset is strong, some prescribers are underwhelmed by ACR20 endpoint. EXTON, PA, March 27, 2025 – In late 2024, Bristol Myers Squibb announced positive topline results from its pivotal Phase 3 trials, POETYK PsA-1 and PsA-2, evaluating Sotyktu (deucravacitinib) in adults with active psoriatic arthritis (PsA). Both trials met their […]
